| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 17.70 | 15.0% |
| Total Income | 17.70 | 15.0% |
| Expenditure | 27.18 | 8.8% |
| PBT | -6.47 | 54.2% |
| Net Profit | -4.93 | 63.7% |
| OPM | -53.58% | 40.22pp |
| NPM | -27.87% | 60.37pp |
| EPS | -0.10 | 63.0% |
Theravance Biopharma Reports Q1 2026 Financial Results
07 May 2026 · 7 May, 6:14 pm
Summary
Theravance Biopharma reported its financial and operational results for the first quarter of 2026. YUPELRI Collaboration Revenue increased by 15% year-over-year, reaching $17.7 million. The company's operating expenses decreased by approximately 20% year-over-year, excluding restructuring items. GSK reported TRELEGY net sales of $873 million, a 2% increase year-over-year. The company's cash balance at the end of the quarter was $395 million, and the Strategic Review Committee is evaluating opportunities to maximize shareholder value.
Key Highlights
- 1
YUPELRI Collaboration Revenue increased 15% year-over-year to $17.7 million, driven by continued Net Sales growth and improved operating leverage.
- 2
All Hatch-Waxman litigation relating to YUPELRI has been resolved following settlement with Mankind Pharma in March.
- 3
Operating Expenses saw a reduction of approximately 20% year-over-year, excluding restructuring items.
- 4
Q1 2026 TRELEGY net sales, reported by GSK, reached $873 million, up 2% year-over-year.
- 5
The company maintains high confidence in achieving the $100 million 2026 milestone payment related to TRELEGY sales.
- 6
The company's quarter-end cash balance stands at $395 million with no debt.
- 7
The Strategic Review Committee is actively evaluating opportunities to maximize shareholder value.
Management Comments
Rick E Winningham
We delivered strong financial performance in the first quarter, reinforcing the quality of our commercial asset, our robust balance sheet and the important actions underway to reshape our cost structure, following the outcome of the CYPRESS study. YUPELRI® continues to deliver sustained net sales growth and expanding profitability, supported by growing community and hospital adoption, improved net pricing, and the recent resolution of generic litigation, driving increased long-term value for the franchise. TRELEGY also continued to perform well, and we remain confident that we will achieve the $100 million milestone payment associated with 2026 net sales. The entire Theravance team is acting with discipline and urgency, and we are confident that the continued execution against our strategic priorities and the Board’s ongoing review process will maximize value for shareholders.
Informational and educational content only. Not investment advice.